<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29898140</article-id><article-id pub-id-type="pmc">5985837</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0088</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Aortic Valve Replacement with a Conventional Stented Bioprosthesis
<italic>versus</italic> Sutureless Bioprosthesis: a Study of 763
Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mujtaba</surname><given-names>Syed Saleem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Ledingham</surname><given-names>Simon M.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Asif Raza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Pillay</surname><given-names>Thasee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Schueler</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><aff id="aff1"><label>1</label> Department of Cardiothoracic Surgery, Freeman
Hospital, Freeman Road, United Kingdom of Great Britain and Northern
Ireland.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Stephen Schueler, Department of
Cardiothoracic Surgery, Freeman Hospital, Freeman Road Newcastle upon Tyne, NE3
1YS, United Kingdom. E-mail: <email>stephan.schueler@nuth.nhs.uk</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2018</year></pub-date><volume>33</volume><issue>2</issue><fpage>122</fpage><lpage>128</lpage><history><date date-type="received"><day>03</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The aim of this retrospective study was to compare early postoperative
outcomes after aortic valve replacement (AVR) with sutureless bioprostheses
and conventional stented bioprostheses implanted through median
sternotomy.</p></sec><sec><title>Methods</title><p>From January 2011 to December 2016, 763 patients underwent aortic valve
replacement with bioprostheses; of these, 139 received a Perceval S
sutureless valve (Group A) and 624 received a Perimount Magna Ease valve
(Group B). These groups were further divided into A1 (isolated Perceval
AVR), A2 (Perceval AVR with coronary artery bypass grafting [CABG]), B1
(isolated conventional stented bioprosthesis), and B2 (conventional stented
bioprosthesis + CABG).</p></sec><sec><title>Results</title><p>Patients in Group A were older (mean 74 years <italic>vs.</italic> 71 years;
<italic>P</italic>&#x0003c;0.0001), predominantly women (53%
<italic>vs.</italic> 32%; <italic>P</italic>&#x0003c;0.0001), had a higher
logistic EuroSCORE (3.26 <italic>vs.</italic> 2.43;
<italic>P&#x0003c;</italic>0.001), more preoperative atrial fibrillation (20%
<italic>vs.</italic> 13%; <italic>P</italic>=0.03), and had a lower
reopening rate for bleeding (2.1% <italic>vs.</italic> 6.7%;
<italic>P</italic>=0.04). Compared to Group B1, Group A1 had shorter
cross-clamp (mean 40 min <italic>vs.</italic> 57 min;
<italic>P</italic>&#x02264;0.0001) and bypass times (mean 63 min vs. mean 80
min; <italic>P</italic>=0.02), and they bled less postoperatively (mean 295
ml <italic>vs.</italic> mean 393 ml; <italic>P</italic>=0.002). The mean
gradient across Perceval valve was 12.5 mmHg while its effective orifice
area was 1.5 cm<sup>2</sup>.</p></sec><sec><title>Conclusion</title><p>In our retrospective study of 763 patients, sutureless valve group patients
are older, mostly women, more symptomatic preoperatively, and have higher
logistic EuroSCORE. They have shorter cross-clamp and bypass times, less
postoperative bleeding, and reduced incidence of reopening. Further studies
are needed to evaluate the clinical benefits in short, mid, and
long-terms.</p></sec></abstract><kwd-group><kwd>Aortic Valve/Surgery</kwd><kwd>Heart Valve Prosthesis/Utilization</kwd><kwd>Heart Valve Prosthesis Implantation</kwd></kwd-group></article-meta></front><body><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic valve
replacement</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CBP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cumulative bypass</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CCC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cumulative
cross-clamp</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EOA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Effective orifice
area</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MPG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mean pressure
gradients</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NASCA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= National Adult Cardiac
Surgery Audit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NICOR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= National Institute for
Cardiovascular Outcomes Research</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PPM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Patient prosthesis
mismatch</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SCTS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Society for
Cardiothoracic Surgeons</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transcatheter aortic
valve implantation</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Aortic valve replacement (AVR) is the treatment of choice for aortic valve stenosis
when it is a symptomatic severe aortic stenosis (&#x02264;1
cm<sup>2</sup>/m<sup>2</sup>) or an asymptomatic with left ventricular
dysfunction or combined with other cardiac surgery procedure<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Surgical AVR still
represents the gold standard treatment in patients with severe aortic valve
stenosis<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Owing to the increasing age of the patient
population in Western world, there has been an increase in the prevalence of
patients with valvular heart disease eligible for AVR<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. A majority of these
geriatric patients are females of small stature with corresponding small aortic
roots. It has been suggested that patient prosthesis mismatch (PPM) may be
associated with less regression of left ventricular hypertrophy and lower
survival<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Given the increasing number of comorbidities and
increasing age of patients, a tendency has emerged to use biological valve implants
thus avoiding the need for long-term anticoagulation therapy. Although the concept
of transcatheter aortic valve implantation (TAVI) appears attractive, the calcified
aortic valve is not removed during this procedure. Therefore paravalvular leakage
remains an important issue with this technique<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Other important concerns are access
site-related problems and device malpositioning.</p><p>The recent introduction of sutureless bioprostheses may offer an additional tool in
the therapeutic armamentarium as these valves do not need to be sutured into place,
resulting in shorter cross-clamp and cardiopulmonary bypass (CPB) times which may be
beneficial in older patients with comorbid conditions. Moreover, due to the absence
of a sewing ring, these valves exhibit favourable hemodynamic properties. Excellent
outcomes have been demonstrated with sutureless AVR in minimally invasive surgical
setting<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>This study provides a comparison between the sutureless Perceval valve and the
conventional stented sutured biological valve in an attempt to better define the
role of sutureless AVR in the treatment of critical aortic valve stenosis.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a retrospective, observational cohort study of consecutive patients with
aortic valve disease who underwent AVR with sutureless and conventional
bioprostheses between January 2011 and December 2016. During this period, 763
patients underwent AVR with bioprostheses. Of these, 139 received a Perceval
sutureless valve (Sorin, Saluggia, Italy) (Group A) and 624 received a
Carpentier-Edwards Perimount Magna Ease aortic valve (Edwards Lifesciences, Irvine,
CA, USA) (Group B). Group A was further divided into isolated Perceval valve (A1)
and Perceval valve combined with coronary artery bypass grafting (CABG) (A2).
Similarly, Group B was further divided into isolated Perimount magna ease (B1) and
Perimount magna ease with CABG (B2). All patients were operated upon by one of six
different surgeons at our institution. Preoperative characteristics and
postoperative data of all these patients were studied retrospectively and Group A
was compared with Group B.</p><p>If the patients had indications for AVR and wished to have a biological valve, they
were given a Perceval valve, provided they had no contraindications. Although the
age range of our patients for Perceval valve is 47-86 years old, very few young
patients (&#x0003c;60 years old) had Perceval valve, as it is evident from mean and
median age. Most of the young patients had a combination of bicuspid and early
degenerative aortic valve stenosis. We totally respected our patient's wishes, if
they preferred to have tissue valve, we provided them with Perceval valve, as long
as they fulfilled the criterion.</p><p>For Perceval valve cases, congenital pure bicuspid aortic valves (Sievers type 0)
with abnormal sinotubular junction (annulus ratio or aortic annulus greater than 27
mm or lesser than 19 mm) were excluded. Patients with ascending aortic aneurysm or
dissection, emergency intervention, acute endocarditis, redo cases and other
combined cases (beside AVR+CABG) were also excluded from both groups.</p><sec><title>Statistical Analysis</title><p>The data used in this analysis were extracted from National Adult Cardiac Surgery
Audit (NASCA) database. This audit is managed by National Institute for
Cardiovascular Outcomes Research (NICOR), with clinical direction and strategy
provided by the Society for Cardiothoracic Surgeons (SCTS) and the Project
Board. Analysis was performed using MS Excel. Numerical values were compared
using an independent t-test, with a two-tailed distribution assuming unequal
variances. Categorical variables were compared using Chi-squared
&#x003c7;<sup>2</sup> analysis.</p></sec><sec><title>Surgical Technique</title><p>After a full median sternotomy, standard CPB was established by cannulation of
the ascending aorta and the right atrium. The heart was vented through the right
superior pulmonary vein or the main pulmonary artery. Antegrade cold blood
cardioplegia was used for myocardial protection. Continuous carbon dioxide
insufflation was used routinely after sternotomy until closure of the aortotomy.
In combined cases, distal end coronary anastomoses were performed before opening
the aorta, and proximal end was performed after the cross-clamp is taken off,
with the side biter on.</p></sec><sec><title>Perceval Valve</title><p>The ascending aorta was incised transversally 1.5 cm above the sinotubular
junction in order to leave a free edge for closure of the aortotomy after
implantation of the device. The aortic valve was removed, and the annulus was
decalcified in the usual fashion. The aortic orifice was measured with valve
manufacturer's sizers.</p><p>Three 4/0 polypropylene guiding sutures were passed through the nadir of the
aortic annulus. An appropriately sized prosthesis was collapsed on a side table
and placed into the delivery system.</p><p>The three guiding sutures were passed through the three guides arising from the
annular ring of the prosthesis, which was consequently seated on the fully
debrided annulus. Once the delivery system was in position, the valve was
deployed by turning the release screw and leaving the valve in place. The
delivery system and guiding sutures were then removed. The field was rinsed with
warm saline, and the prosthesis was dilated at four atmospheres for 30
seconds.</p></sec><sec><title>Perimount Magna Valve</title><p>A transverse aortotomy was made 2 cm above the right coronary artery.
Semicontinuous 2/0 Prolene sutures or interrupted non-pledgeted Ethibond sutures
were used to stitch the aortic valve to the annulus. After closure of the
aortotomy, transesophageal echocardiography was performed to assess the correct
implantation of the prosthesis and the presence of any paravalvular leak.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Preoperative patient characteristics are outlined in <xref ref-type="table" rid="t1">Tables 1</xref> and <xref ref-type="table" rid="t2">2</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Preoperative summary.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group A</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group B</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Chi-squared test</th></tr><tr><th align="center" rowspan="1" colspan="1">n =139</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n =624</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (M/F)</td><td align="center" rowspan="1" colspan="1">65/74</td><td align="center" rowspan="1" colspan="1">47/53</td><td align="center" rowspan="1" colspan="1">459/215</td><td align="center" rowspan="1" colspan="1">68/32</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td colspan="6" align="left" rowspan="1">Procedure types</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated aortic valve replacement</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">426</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;AVR+CABG or other procedures</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">198</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">History of cigarette smoking</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">410</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">History of hypertension</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">418</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal disease at time of surgery</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.70</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0.80</td><td align="center" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">History of pulmonary disease, <italic>i.e</italic>.
COPD, asthma</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">23.02</td><td align="center" rowspan="1" colspan="1">126</td><td align="center" rowspan="1" colspan="1">20.19</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">History of neurological disease, <italic>i.e</italic>.
TIA, CVA</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td colspan="6" align="left" rowspan="1">Angina status before surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0. No angina</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">316</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. No limitation of physical activity</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">127</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Slight limitation of ordinary activity</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Marked limitation of ordinary physical
activity</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;4. Symptoms at rest or minimal activity</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Angina symptoms</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">64.7</td><td align="center" rowspan="1" colspan="1">308</td><td align="center" rowspan="1" colspan="1">49.4</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td colspan="6" align="left" rowspan="1">Dyspnoea status before surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. No limitation of physical activity</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">8.70</td><td align="center" rowspan="1" colspan="1">122</td><td align="center" rowspan="1" colspan="1">19.55</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Slight limitation of ordinary physical
activity</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">264</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Marked limitation of ordinary physical
activity</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">220</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;4. Symptoms at rest or minimal activity</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnoea symptoms</td><td align="center" rowspan="1" colspan="1">127</td><td align="center" rowspan="1" colspan="1">91.4</td><td align="center" rowspan="1" colspan="1">502</td><td align="center" rowspan="1" colspan="1">80.4</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">History of diabetes mellitus</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">0.53</td></tr><tr><td colspan="6" align="left" rowspan="1">Preoperative heart rhythm</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0. Sinus rhythm</td><td align="center" rowspan="1" colspan="1">109</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">530</td><td align="center" rowspan="1" colspan="1">84.94</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. Atrial fibrillation/flutter</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Complete heart block/pacing</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1.40</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Other abnormal rhythm</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td colspan="6" align="left" rowspan="1">Ejection fraction category</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. Good (LVEF &#x0003e; 50%)</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">498</td><td align="center" rowspan="1" colspan="1">79.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Fair (LVEF 30-50%)</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Poor (LVEF &#x0003c; 30%)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">0.35</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AVR=aortic valve replacement; CABG=coronary artery bypass grafting;
COPD=chronic obstructive pulmonary disease;</p><p>CVA=cerebrovascular accident; F=female; LVEF=left ventricular ejection
fraction; M=male; TIA=transient ischemic attack</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Preoperative summary (comparison between Groups A and B).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group A range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Group B range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age of patients at time of procedure</td><td align="center" rowspan="1" colspan="1">47-86</td><td align="center" rowspan="1" colspan="1">74.3</td><td align="center" rowspan="1" colspan="1">75.5</td><td align="center" rowspan="1" colspan="1">34-91</td><td align="center" rowspan="1" colspan="1">71.74</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE comparison</td><td align="center" rowspan="1" colspan="1">0.53-18.886</td><td align="center" rowspan="1" colspan="1">3.26</td><td align="center" rowspan="1" colspan="1">2.46</td><td align="center" rowspan="1" colspan="1">0-16.527</td><td align="center" rowspan="1" colspan="1">2.43</td><td align="center" rowspan="1" colspan="1">1.84</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">140-185</td><td align="center" rowspan="1" colspan="1">162</td><td align="center" rowspan="1" colspan="1">162</td><td align="center" rowspan="1" colspan="1">138-190</td><td align="center" rowspan="1" colspan="1">166.30</td><td align="center" rowspan="1" colspan="1">167</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">40.3-158</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">44.9-181.6</td><td align="center" rowspan="1" colspan="1">81.47</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">0.13</td></tr></tbody></table></table-wrap><p>There was no difference between Groups A and B in history of preoperative renal
impairment or pulmonary disease. Group A had more female patients (A=53%
<italic>vs.</italic> B=32%; <italic>P</italic>&#x0003c;0.0001) and patients with
hypertension (76% <italic>vs.</italic> 67%; <italic>P</italic>=0.03) and
neurological dysfunction (18% <italic>vs.</italic> 11%; <italic>P</italic>=0.03).
Also, Group A had more patients with angina (90% vs. 49%; <italic>P</italic>=0.001),
dyspnoea (91% <italic>vs.</italic> 80%; <italic>P</italic>=0.002), and preoperative
atrial fibrillation (AF) (20% <italic>vs.</italic> 13%; <italic>P</italic>=0.03). In
Group A, patients were older (range: 47-86 years old, mean 74 <italic>vs.</italic>
range 34-91, mean 71; <italic>P</italic>=0.0001) and had a higher logistic EuroSCORE
(3.26 <italic>vs.</italic> 2.43; <italic>P</italic>=0.001).</p><p>Intraoperative and early postoperative variables are summarized in <xref ref-type="table" rid="t3">Tables 3</xref> and <xref ref-type="table" rid="t4">4</xref>. Cross-clamp (range 21-114 min, mean 40 min <italic>vs.</italic> range
24-164 min, mean 57 min; <italic>P</italic>&#x0003c;0.0001) and bypass times (range
25-172 min, mean 63 min <italic>vs.</italic> range 19-285 min, mean 80 min;
<italic>P</italic>=0.002) were shorter in the isolated Perceval valve group
(Group A1) compared to the isolated conventional valve group (Group B1). When A2
(Perceval valve + CABG) was compared with B2 (conventional valve + CABG), A2 had a
shorter cross-clamp time (range 28-127 min, mean 68 min <italic>vs.</italic> range
40-177, mean 78 min; <italic>P</italic>=0.02), but no significant difference was
found in bypass time (range 38-403 min, mean 107 min <italic>vs.</italic> range
60-280 min, mean 112 min; <italic>P</italic>=0.51).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Intraoperative and early postoperative summary of isolated AVR.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">Intraoperative and early postoperative
summary</th><th align="center" rowspan="1" colspan="1">Isolated AVR: Perceval</th><th align="center" colspan="2" rowspan="2">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Isolated AVR: Perimount</th><th align="center" colspan="2" rowspan="2">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Isolated valve</th></tr><tr><th align="center" rowspan="1" colspan="1">Group A1 n=92</th><th align="center" rowspan="1" colspan="1">Group B1 n=426</th><th align="center" rowspan="1" colspan="1">Group A</th></tr><tr><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cumulative cross-clamp time (min)</td><td align="center" rowspan="1" colspan="1">21-114</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">24-164</td><td align="center" rowspan="1" colspan="1">56.6</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cumulative bypass time</td><td align="center" rowspan="1" colspan="1">25-172</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">19-285</td><td align="center" rowspan="1" colspan="1">80.1</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative blood loss at 12 hours</td><td align="center" rowspan="1" colspan="1">50-2000</td><td align="center" rowspan="1" colspan="1">295</td><td align="center" rowspan="1" colspan="1">225</td><td align="center" rowspan="1" colspan="1">100-2725</td><td align="center" rowspan="1" colspan="1">393.3</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay in days</td><td align="center" rowspan="1" colspan="1">1-32</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1-34</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.07</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AVR=aortic valve replacement; ICU=intensive care unit</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Intraoperative and early postoperative summary of AVR+CABG.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="30%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="3" colspan="1">Intraoperative and early postoperative
summary</th><th align="center" rowspan="1" colspan="1">Perceval AVR+CABG</th><th align="center" colspan="2" rowspan="2">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Perimount AVR+CABG</th><th align="center" colspan="3" rowspan="2">&#x000a0;</th></tr><tr><th align="center" rowspan="1" colspan="1">Group A2 n=47</th><th align="center" rowspan="1" colspan="1">Group B2 n=198</th></tr><tr><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cumulative cross-clamp time (min)</td><td align="center" rowspan="1" colspan="1">28-127</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">40-177</td><td align="center" rowspan="1" colspan="1">78.3</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Cumulative bypass time</td><td align="center" rowspan="1" colspan="1">38-403</td><td align="center" rowspan="1" colspan="1">107</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">60-280</td><td align="center" rowspan="1" colspan="1">112.7</td><td align="center" rowspan="1" colspan="1">107</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative blood loss at 12 hours</td><td align="center" rowspan="1" colspan="1">50-1200</td><td align="center" rowspan="1" colspan="1">457</td><td align="center" rowspan="1" colspan="1">400</td><td align="center" rowspan="1" colspan="1">100-2825</td><td align="center" rowspan="1" colspan="1">484.9</td><td align="center" rowspan="1" colspan="1">380</td><td align="center" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay in days</td><td align="center" rowspan="1" colspan="1">1-93</td><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1-34</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.09</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>AVR=aortic valve replacement; CABG=coronary artery bypass grafting;
ICU=intensive care unit</p></fn></table-wrap-foot></table-wrap><p>The mean gradient across Perceval valve was found to be higher for the smaller valves
and lower for the larger valves. It ranges from 6-18 mmHg and its mean value was
12.5 mmHg. Similarly, its effective orifice area (EOA) varies according to the valve
sizes, but its mean value was 1.5 cm<sup>2</sup>.</p><p>The incidence of complications over the early postoperative course is depicted in
<xref ref-type="table" rid="t5">Table 5</xref>. In this study, we used first 12
hours drainage, as traditionally first 12 hours drainage is recorded in NASCA
database and it is easy to retrieve. Most of the time it is the total drainage, but
not always.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Postoperative summary (comparison between Groups A and B).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Postoperative summary</th><th align="center" rowspan="1" colspan="1">Group A: Perceval</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group B: Perimount</th><th align="center" colspan="2" rowspan="1">&#x000a0;</th></tr><tr><th align="center" rowspan="1" colspan="1">n = 139</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n = 624</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Reoperation for bleeding, tamponade, or valvular
problems</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2.10%</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">6.73%</td><td align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Sternal wound infection</td><td align="center" rowspan="1" colspan="1">2/139</td><td align="center" rowspan="1" colspan="1">1.43%</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">2.24%</td><td align="center" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">New postoperative neurological dysfunction</td><td align="center" rowspan="1" colspan="1">4/139</td><td align="center" rowspan="1" colspan="1">2.80%</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">1.44%</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">New HF/dialysis postoperatively</td><td align="center" rowspan="1" colspan="1">5/139</td><td align="center" rowspan="1" colspan="1">3.60%</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">5.93%</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient status at discharge (mortality)</td><td align="center" rowspan="1" colspan="1">3/139</td><td align="center" rowspan="1" colspan="1">2.10%</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">2.40%</td><td align="center" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">SIRS</td><td align="center" rowspan="1" colspan="1">21/139</td><td align="center" rowspan="1" colspan="1">15%</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">18%</td><td align="center" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Arrhythmias</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">None</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">63%</td><td align="center" rowspan="1" colspan="1">342</td><td align="center" rowspan="1" colspan="1">55%</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">AF/Flutter</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">33%</td><td align="center" rowspan="1" colspan="1">258</td><td align="center" rowspan="1" colspan="1">41%</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Permanent pacemaker</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.60%</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">1.92%</td><td align="center" rowspan="1" colspan="1">0.23</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>AF=atrial fibrillation; HF=haemofiltration; SIRS=systemic inflammatory
response syndrome</p></fn></table-wrap-foot></table-wrap><p>Isolated Perceval group (Group A1) had less bleeding in first 12 hours compared to
the isolated conventional valve group (Group B1) (range 50-2000 ml, mean 295 ml
<italic>vs.</italic> range 100-2725 ml, mean 393 ml; <italic>P</italic>=0.002),
but there was no significant difference when A2 (Perceval valve + CABG) was compared
with B2 (conventional valve + CABG) (range 50-1200 ml, mean 457 ml
<italic>vs.</italic> range 100-2825 ml, mean 485 ml; = 0.58). There were more
patients reoperated for bleeding or tamponade in Group B than in Group A (2.1%
<italic>vs.</italic> 6.7%; <italic>P</italic>=0.04). There was no significant
difference in postoperative neurological dysfunction, renal impairment, AF,
permanent pacemaker requirement, or mortality.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>New scientific and technologic achievements have allowed a continuous decrease in
mortality and morbidity for AVR, in spite of the more complex and elderly patients
being referred for surgery. The primary goal of AVR is to alleviate the pressure
overload on the left ventricle and to allow regression as well as remodelling of the
left ventricular mass. A smaller-sized prosthetic valve may result in so-called
PPM.</p><p>Therefore, different options have been proposed for patients with small aortic root
presenting for AVR, <italic>i.e.</italic>: stentless valves, aortic root
enlargement, and even complete aortic root replacement. However, all these options
are technically more complex and take a longer operating time. Hence, they have not
been popular with surgeons.</p><p>Magovern et al.<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup> introduced the concept of sutureless aortic valve in
the 1960s with a ball-cage-type mechanical valve for sutureless implantation. It had
its own disadvantages<italic>, i.e.</italic>: high incidence of paravalvular leaks,
bulky size and it was not suitable for small annuli<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. There was a high
incidence of thromboembolism (42%) and reoperation (16%). This valve continued to be
used however until 1980.</p><p>The introduction of sutureless bioprostheses in the last decade offered a unique
therapeutic opportunity given the possibility to potentially yield the advantages of
a traditional surgical valve replacement (as the native valve can be fully excised)
and a transcatheter approach (as it can be rapidly implanted). Moreover, aortic
cross-clamp and total cardiopulmonary times are also reduced.</p><p>Therefore, the aim of the current study was to analyse and compare the early clinical
outcomes of conventional AVR with a sutureless valve prosthesis.</p><p>Shrestha et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> highlighted the advantages of sutureless valves for
geriatric patients with small aortic roots. They showed that Perceval sutureless
valve implants are associated with shorter cross-clamp and CPB times compared to
conventional biological valves, even though most of these patients were operated on
via minimally invasive access.</p><p>Moreover, due to the absence of a sewing ring, these valves have favourable EOA and
haemodynamics for any given size. This may potentially result in better
haemodynamics even without root enlargement in small annular sizes.</p><p>Gilmanov et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> reviewed 515 patients undergoing primary AVR
through a right anterior mini-thoracotomy (269 conventional <italic>vs</italic>. 246
sutureless prostheses). They showed that the use of Perceval sutureless valve had
shorter cross-clamp, bypass, and mechanical ventilation times. Pollari et
al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>
studied 566 patients who underwent AVR with bioprostheses. Of these, 166 received a
sutureless valve and 400 received a stented valve. Aortic cross-clamp and CPB times
were significantly shorter in the sutureless group. Patients from the sutureless
group required blood transfusion less frequently and had shorter intensive care unit
(ICU) stay, hospital stay, and intubation time.</p><p>A shorter procedural time in the sutureless group is associated with better clinical
outcomes and reduced hospital costs. Dal&#x000e9;n et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> compared 182 patients
who underwent a ministernotomy with a sutureless bioprosthesis and 383 patients who
had full sternotomy with a stented bioprosthesis. They concluded that sutureless
bioprostheses were associated with shorter aortic cross-clamp and CPB times and less
blood transfusion.</p><p>In our study, the Perceval valve group had lower incidence of total drainage and
re-exploration rate. We think it happens because of a short bypass time. We have
clearly shown that Perceval valve patients have shorter cross-clamp and bypass times
and lower incidence of postoperative bleeding, but longer ICU stay (not
statistically significant). We think that if these patients had had a traditional
Perimount Magna Ease valve, they might have had a potentially longer ICU stay. It is
only an assumption, but we need to do a randomised control trial to prove it.</p><p>Additionally, in our study, patients with isolated AVR with Perceval valve spent 3.4
days (mean) and 1 day (median) in ICU. Gilmanov et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> observed the same ICU
stay as 1 day (median). In other studies, ICU stay was not very different,
<italic>i.e.</italic>: Shrestha et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> (1.8&#x000b1;1.8 days), Pollari et
al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>
(2&#x000b1;1.2 days), and Dal&#x000e9;n et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> (2.4&#x000b1;2.4 days).</p><p>Our results correlated well with those from Shrestha et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> and Gilmanov et
al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>,
although they operated on small aortic root and through right mini-thoracotomy,
respectively. Pollari et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> also had shorter cross-clamp and bypass times
like us, but contrary to our study, their ICU stay was shorter in the Perceval
group. Our results also matched those from Dal&#x000e9;n et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>, but they showed less
blood transfusion, which we did not.</p><p>Our cumulative cross-clamp (CCC) and cumulative bypass (CBP) times for isolated AVR
with Perceval valve match quite well with those from previous studies. Our mean CCC
&#x00026; CBP times are 40 and 63 minutes, respectively. The same times for Shrestha et
al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>
were 30.1&#x000b1;9.0/58.7&#x000b1;20.9 minutes, although most of these patients were
operated on via minimally invasive access. Pollari et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> reported CCC &#x00026; CBP
times of 35&#x000b1;12 and 71&#x000b1;11 minutes, respectively, but they also included
some redo cases. CCC &#x00026; CBP times for Dalen et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> were 40&#x000b1;15 and
69&#x000b1;20 minutes, respectively, although they performed their surgeries via
ministernotomy. Gilmanov et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> implanted Perceval valve through right
mini-thoracotomy and their median CCC &#x00026; CBP times were 56 and 90 minutes,
respectively. All these studies, including ours, showed shorter CCC &#x00026; CBP times
compared to conventional biological valve and this difference was statistically
significant. Prolonged aortic cross-clamp time significantly correlates with major
postoperative morbidity and mortality in both low- and high-risk cardiac surgery
patients. This effect increases with prolonged cross-clamp
time<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Al-Sarraf et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> have shown that by
using cross-clamp time as a continuous variable, an incremental increase of 1 min
interval in cross-clamp time was associated with a 2% increase in mortality in both
low- and high-risk groups. In addition, high-risk patient populations such as those
with diabetes or depressed left ventricular ejection fraction (LVEF) were found to
benefit the most from a reduction in aortic cross-clamp time<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>Our mean pressure gradients (MPG) and EOA were comparable with the values reported in
literature for Perceval valves. Folliguet et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> (10.4&#x000b1;4.3
mmHg), Santarpino et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> (13.4&#x000b1;2.8 mmHg), Flameng et
al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> (11 range 5-28 mmHg), D'Onofrio et
al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> (10.95&#x000b1;3.72 mmHg), and the Cavalier
Trial<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> (10.24 mmHg) reported pre-discharge MPG, while
Shrestha et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> discussed 12-month follow-up data (10&#x000b1;5
mmHg). Our EOA was also compatible with the Cavalier study
results<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> (1.46 cm<sup>2</sup>).</p><p>In our study, the Perceval group includes older patients, more women, and more
comorbidities, as evident by a higher logistic EuroSCORE. Although their
postoperative drainage is lower, because of more comorbidities and for being sicker,
they spent more time in ICU, but this difference was not statistically significant.
Moreover, higher logistic EuroSCORE was not reflected in a higher mortality, as the
difference was not statistically significant. Maybe the factor of a higher
comorbidity was buffered by a shorter cross-clamp time.</p><sec><title>Limitations</title><p>This study carries all the limitations that a retrospective analysis design
implies. Patients in the sutureless group were operated upon more recently than
the majority of those receiving conventional valves. Propensity matching is not
performed which could have provided more accurate comparison.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Despite the limits of its retrospective design, this study represents the largest
single-center comparison between Perceval sutureless valve and conventional
bioprostheses for AVR. We observed that in our study of 763 patients, sutureless
valve group patients are older, mostly women, more symptomatic, and have higher
logistic EuroSCORE. Despite this, those operated on with the Perceval valve showed
shorter cross-clamp and bypass times, less postoperative bleeding, and a reduced
incidence of reopening. Further studies are needed to evaluate the clinical benefits
in short, mid and long-terms.</p><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SSM</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">SML</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published </td></tr><tr><td align="left" rowspan="1" colspan="1">ARS</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">TP</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">SS</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">SC</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the conception or design
of the work; or the acquisition, analysis, or interpretation of data
for the work; final approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Department of Cardiothoracic Surgery, Freeman
Hospital, Freeman Road, United Kingdom of Great Britain and Northern
Ireland.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Carabello</surname><given-names>BA</given-names></name><name><surname>Erwin</surname><given-names>JP 3rd</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><etal/><collab>ACC/AHA Task Force Members</collab></person-group><article-title>2014 AHA/ACC Guidelines for the management of patients with
valvular heart disease: executive summary: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines</article-title><source>Circulation</source><year>2014</year><volume>129</volume><issue>23</issue><fpage>2440</fpage><lpage>2492</lpage><pub-id pub-id-type="pmid">24589852</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Alfieri</surname><given-names>O</given-names></name><name><surname>Andreotti</surname><given-names>F</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name><name><surname>Bar&#x000f3;n-Esquivias</surname><given-names>G</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><etal/><collab>ESC Committee for Practice Guidelines (CPG)</collab><collab>Joint Task Force on the Management of Valvular Heart Disease of the
European Society of Cardiology (ESC)</collab><collab>European Association for Cardio-Thoracic Surgery (EACTS)</collab></person-group><article-title>Guidelines on the management of valvular heart disease (version
2012): the Joint Task Force on the Management of Valvular Heart Disease of
the European Society of Cardiology (ESC) and the European Association for
Cardio-Thoracic Surgery (EACTS)</article-title><source>Eur J Cardiothorac Surg</source><year>2012</year><volume>42</volume><issue>4</issue><fpage>S1</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22922698</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bridgewater</surname><given-names>B</given-names></name><name><surname>Gummert</surname><given-names>J</given-names></name><name><surname>Kinsman</surname><given-names>R</given-names></name><name><surname>Walton</surname><given-names>P</given-names></name></person-group><source>Towards global benchmarking: the Fourth EACTS Adult Cardiac Surgical
Database Report</source><publisher-name>Dendrite Clinical Systems</publisher-name><publisher-loc>Henley-on-Thames, Oxfordshire</publisher-loc><year>2010</year></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohty</surname><given-names>D</given-names></name><name><surname>Dumesnil</surname><given-names>JG</given-names></name><name><surname>Echahidi</surname><given-names>N</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name><name><surname>Dagenais</surname><given-names>F</given-names></name><name><surname>Voisine</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of prosthesis-patient mismatch on long-term survival after
aortic valve replacement: influence of age, obesity, and left ventricular
dysfunction</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><issue>1</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">19118723</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>S</given-names></name><name><surname>Sadowski</surname><given-names>J</given-names></name><name><surname>Eckstein</surname><given-names>FS</given-names></name><name><surname>Bartus</surname><given-names>K</given-names></name><name><surname>Kapelak</surname><given-names>B</given-names></name><name><surname>Sievers</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Clinical experience with the ATS 3f Enable&#x000ae; sutureless
bioprosthesis</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><issue>3</issue><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">21342776</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name><name><surname>Concistr&#x000e8;</surname><given-names>G</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name></person-group><article-title>Perceval S aortic valve implantation in mini-invasive surgery:
the simple sutureless solution</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2012</year><volume>15</volume><issue>3</issue><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">22617506</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magovern</surname><given-names>GJ</given-names></name><name><surname>Cromie</surname><given-names>HW</given-names></name></person-group><article-title>Sutureless prosthetic heart valves</article-title><source>J Thorac Cardiovasc Surg</source><year>1963</year><volume>46</volume><fpage>726</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">14099081</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>SM</given-names></name><name><surname>Sethi</surname><given-names>GK</given-names></name><name><surname>Flye</surname><given-names>MW</given-names></name><name><surname>Takaro</surname><given-names>T</given-names></name></person-group><article-title>The sutureless aortic valve prosthesis: experience with and
technical considerations for replacement of the early model</article-title><source>Ann Surg</source><year>1976</year><volume>184</volume><issue>2</issue><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">133642</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>M</given-names></name><name><surname>Maeding</surname><given-names>I</given-names></name><name><surname>H&#x000f6;ffler</surname><given-names>K</given-names></name><name><surname>Koigeldiyev</surname><given-names>N</given-names></name><name><surname>Marsch</surname><given-names>G</given-names></name><name><surname>Siemeni</surname><given-names>T</given-names></name><etal/></person-group><article-title>Aortic valve replacement in geriatric patients with small aortic
roots: are sutureless valves the future?</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2013</year><volume>17</volume><issue>5</issue><fpage>778</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">23851988</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilmanov</surname><given-names>D</given-names></name><name><surname>Miceli</surname><given-names>A</given-names></name><name><surname>Ferrarini</surname><given-names>M</given-names></name><name><surname>Farneti</surname><given-names>P</given-names></name><name><surname>Murzi</surname><given-names>M</given-names></name><name><surname>Solinas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Aortic valve replacement through right anterior minithoracotomy:
can sutureless technology improve clinical outcomes?</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>98</volume><issue>5</issue><fpage>1585</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">25200732</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollari</surname><given-names>F</given-names></name><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Dell'Aquila</surname><given-names>AM</given-names></name><name><surname>Gazdag</surname><given-names>L</given-names></name><name><surname>Alnahas</surname><given-names>H</given-names></name><name><surname>Vogt</surname><given-names>F</given-names></name><etal/></person-group><article-title>Better short-term outcome by using sutureless valves: a
propensity-matched score analysis</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>98</volume><issue>2</issue><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">24928678</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Biancari</surname><given-names>F</given-names></name><name><surname>Rubino</surname><given-names>AS</given-names></name><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Glaser</surname><given-names>N</given-names></name><name><surname>De Praetere</surname><given-names>H</given-names></name><etal/></person-group><article-title>Aortic valve replacement through full sternotomy with a stented
bioprosthesis versus minimally invasive sternotomy with a sutureless
bioprosthesis</article-title><source>Eur J Cardiothorac Surg</source><year>2016</year><volume>49</volume><issue>1</issue><fpage>220</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">25653252</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Sarraf</surname><given-names>N</given-names></name><name><surname>Thalib</surname><given-names>L</given-names></name><name><surname>Hughes</surname><given-names>A</given-names></name><name><surname>Houlihan</surname><given-names>M</given-names></name><name><surname>Tolan</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cross-clamp time is an independent predictor of mortality and
morbidity in low- and high-risk cardiac patients</article-title><source>Int J Surg</source><year>2011</year><volume>9</volume><issue>1</issue><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">20965288</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranucci</surname><given-names>M</given-names></name><name><surname>Frigiola</surname><given-names>A</given-names></name><name><surname>Menicanti</surname><given-names>L</given-names></name><name><surname>Castelvecchio</surname><given-names>S</given-names></name><name><surname>Vincentiis</surname><given-names>C</given-names></name><name><surname>Pistuddi</surname><given-names>V</given-names></name></person-group><article-title>Aortic cross-clamp time, new prostheses, and outcome in aortic
valve replacement</article-title><source>J Heart Valve Dis</source><year>2012</year><volume>21</volume><issue>6</issue><fpage>732</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">23409353</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folliguet</surname><given-names>TA</given-names></name><name><surname>Laborde</surname><given-names>F</given-names></name><name><surname>Zannis</surname><given-names>K</given-names></name><name><surname>Ghorayeb</surname><given-names>G</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><name><surname>Shrestha</surname><given-names>M</given-names></name></person-group><article-title>Sutureless perceval aortic valve replacement: results of two
European centers</article-title><source>Ann Thorac Surg</source><year>2012</year><volume>93</volume><issue>5</issue><fpage>1483</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">22541180</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>J</given-names></name><name><surname>Concistr&#x000e8;</surname><given-names>G</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name></person-group><article-title>Sutureless aortic valve replacement: first-year single-center
experience</article-title><source>Ann Thorac Surg</source><year>2012</year><volume>94</volume><issue>2</issue><fpage>504</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">22695049</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flameng</surname><given-names>W</given-names></name><name><surname>Herregods</surname><given-names>MC</given-names></name><name><surname>Hermans</surname><given-names>H</given-names></name><name><surname>Van der Mieren</surname><given-names>G</given-names></name><name><surname>Vercalsteren</surname><given-names>M</given-names></name><name><surname>Poortmans</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effect of sutureless implantation of the Perceval S aortic valve
bioprosthesis on intraoperative and early postoperative
outcomes</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>142</volume><issue>6</issue><fpage>1453</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">21474151</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Onofrio</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Lorusso</surname><given-names>R</given-names></name><name><surname>Alfieri</surname><given-names>OR</given-names></name><name><surname>Fusari</surname><given-names>M</given-names></name><name><surname>Rubino</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sutureless aortic valve replacement as an alternative treatment
for patients belonging to the "gray zone" between transcatheter aortic valve
implantation and conventional surgery: a propensity-matched, multicenter
analysis</article-title><source>J Thorac Cardiovasc Surg</source><year>2012</year><volume>144</volume><issue>5</issue><fpage>1010</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">22974713</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laborde</surname><given-names>F</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name><name><surname>Hakim-Meibodi</surname><given-names>K</given-names></name><name><surname>Misfeld</surname><given-names>M</given-names></name><name><surname>Carrel</surname><given-names>T</given-names></name><name><surname>Zembala</surname><given-names>M</given-names></name><etal/><collab>Cavalier Trial Investigators</collab></person-group><article-title>Clinical and haemodynamic outcomes in 658 patients receiving the
Perceval sutureless aortic valve: early results from a prospective European
multicentre study (the Cavalier Trial)</article-title><source>Eur J Cardiothorac Surg</source><year>2016</year><volume>49</volume><issue>3</issue><fpage>978</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">26245628</pub-id></element-citation></ref></ref-list></back></article>